Annual US burden
$173 billion
Annual US direct medical cost
Source: CDC 2019
Loading content…
Condition
Obesity / Chronic Weight Management
Obesity (BMI 30+ or 27+ with comorbidity) is recognized as a chronic disease by AMA, WHO, and FDA. GLP-1 therapies produce 15-22% mean weight loss at one year. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Evidence grade: A. STEP and SURMOUNT trial programs established mean total body weight loss of approximately 15% with semaglutide 2.4 mg and approximately 21% with tirzepatide 15 mg at 72 weeks. Saxenda (liraglutide 3.0 mg) is also approved but less effective. Weight regain is common after discontinuation, so most experts treat obesity as chronic and indefinite, similar to hypertension.
Quick answer
UpdatedObesity is a chronic, complex disease characterized by excess adipose tissue that increases health risk. The AMA classified obesity as a disease in 2013. Approximately 100 million US adults (42.4%) have obesity (BMI ≥30); another 30%+ have overweight. GLP-1 receptor agonists (Wegovy 14.9% loss, Zepbound 22.5% loss) are the most effective non-surgical pharmacotherapy ever FDA-approved for chronic weight management.
- US prevalence: ~100 million adults (42.4%)
- CDC NHANES 2017-2020 data
- Annual US cost: ~$173 billion direct medical cost
- CDC 2019
- Wegovy efficacy: 14.9% body weight reduction
- STEP-1 trial, 68 weeks
- Zepbound efficacy: 22.5% body weight reduction
- SURMOUNT-1 trial, 72 weeks (highest in class)
- Cardiovascular benefit: 20% MACE reduction (Wegovy SELECT)
- Adults with obesity + established CVD